INTRODUCTION
Acid-suppressive medications such as proton pump inhibitors and histamine type 2 (H2) receptor antagonists are used to prevent stress ulcers. Theoretically, the inhibition of gastric acid secretion can be associated with increased gastric colonization as well as retrograde colonization of the pharynx leading to VAP with potential micro-aspiration. Some studies have reported that the incidence of hospital-acquired pneumonia increases by 30% following pharmacological stress ulcer prophylaxis (1) (2) (3) . Considering their different mechanisms of action, it is assumed that these drugs have different effects on the incidence of VAP. Various studies have evaluated the effect of different medications on VAP. It was demonstrated that sucralfate, which does not raise gastric pH compared with other conventional prophylactic agents such as H2 blockers, did not increase the incidence of VAP
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Currently, pantoprazole is administered widely for stress ulcer prophylaxis because of its greater efficacy in maintaining a constant elevated gastric pH (8) .
Pantoprazole inhibits gastric acid secretion more effectively in patients admitted to the ICUs and may lead to higher bacterial colonization (9) . Some other studies have shown that pantoprazole is associated with increased rates of community-acquired pneumonia compared with ranitidine (10) (11) (12) , while other studies have not confirmed such findings (13) .Higher risk of hospital acquired pneumonia in patients on pantoprazole without mechanical ventilation has also been reported (3) . We only found a historical cohort study in the literature comparing the effect of ranitidine and pantoprazole and reporting the incidence of VAP to be three times higher in patients receiving pantoprazole (14) . In a meta-analysis, no statistically significant difference was observed between pantoprazole and ranitidine in prevention of gastrointestinal bleeding, risk of VAP or mortality. The researchers ultimately recommended the conduction of more randomized clinical trials in this regard (15) .
We aimed to compare the effects of ranitidine and pantoprazole on VAP. A total of 146 patients were chosen to participate in this study. Of them, 120 patients meeting the inclusion criteria were examined. All patients were followed up until discharge. The patients were randomized using online random allocation software (www.allocationsoftware.com). The patients and the attending intensivists responsible for data collection were blinded to the assigned groups. The patients receiving ranitidine experienced VAP one day earlier than those who received pantoprazole (P=0.683, Table 2 ). The incidence of VAP was 10% and 30% in patients receiving ranitidine and pantoprazole, respectively (P=0.006). There was no significant difference between the two groups with respect to the duration of tracheal intubation. However, the patients treated with pantoprazole stayed at the hospital two days longer than the other patients (P=0.027). Although there was an evident difference in the rate of mortality between the two groups, we found no significant difference in the hospital mortality rate between the two groups (P=0.245). Table 3 shows comparison of patients with respect to the incidence of VAP. As shown, no significant difference was observed between patients with and without VAP with respect to their age, sex, and APACH II scores. VAP patients stayed at the hospital for 12 more days during the treatment process (P=0.000), and tolerated mechanical ventilation for 8 more days (P=0.000) compared to non-VAP patients. However, the two groups had almost similar mortality rates (P=0.572). (3, 10) . Minao and colleagues conducted a cohort study to compare pantoprazole and ranitidine in the development of VAP. They reported that the incidence rate of VAP was significantly higher in patients who received pantoprazole (10, 14) . However, a meta-analysis showed no statistically significant difference between pantoprazole and ranitidine in preventing gastrointestinal bleeding, risk of VAP or mortality.
MATERIALS AND METHODS
Conduction of more clinical trials was also recommended (15) . To the best of our knowledge, our study was the first double-blind randomized controlled trial comparing the effect of these two commonly used medications for preventing stress ulcers in causing VAP.
We found that the incidence of VAP was 10% and 30%
in patients receiving ranitidine and pantoprazole, respectively. We observed no significant difference between the two groups regarding the duration of tracheal intubation. However, the patients treated with pantoprazole stayed at the hospital for two more days compared with those receiving ranitidine. The rate of hospital mortality was not significantly different between the two groups.
In a historical cohort study on 1,682 patients who underwent cardiac surgery in the United States, the incidence rates for VAP were 9.3% and 1.5% in patients receiving pantoprazole and ranitidine for the prevention of stress ulcers, respectively (14) . The researchers of the mentioned study suggested that this relationship needs to be further assessed in a randomized controlled trial.
In a clinical trial conducted by Somberg and colleagues hours were excluded from the study, the definition of VAP did not apply to the mentioned.
In another study, omeprazole and ranitidine were compared with respect to gastrointestinal bleeding. No difference was detected in the incidence rate of VAP as a secondary outcome. In the mentioned study, 150 mg ranitidine was administered intravenously and compared with 40 mg pantoprazole administered orally (19) .
However, this dosage differed from the one we used in our study.
In We did not assess the success rate of the two understudy medications in reducing gastrointestinal bleeding. Proton pump inhibitors prove to be more successful than H2 blockers in decreasing the incidence of gastrointestinal bleeding induced by the stress ulcers because of better gastric acid suppression and gastric pH elevation (8, 9) . It should be noted that mortality rates are much lower in patients with VAP compared to patients with gastrointestinal bleeding. However, stress ulcer prophylaxis is still a controversial issue. 40-70% of admitted patients receive stress ulcer prophylaxis, 70% of which are at a low risk of developing stress ulcers.
Therefore, these medications should be administered with care and upon indication (24) .
In conclusion, patients in ICUs have a three-fold increased risk of developing VAP using pump inhibitors in comparison with H2-blockers. Therefore, the prevention of stress ulcers should be limited to its own specific indications. Such indications for the use of prophylactic drugs should be developed for administering these two medications for specific cases and limit the use of proton pump inhibitors to the patients at a high risk for gastrointestinal bleeding.
